Description: ReFocus is an annual global conference for senior-level life insurance and reinsurance executives hosted jointly by ACLI and the Society of Actuaries (SOA). This event features top-notch speakers, thought-provoking sessions, and superior networking opportunities.

Description: In today’s market of post-pandemic consolidation and org chart streamlining, we’ve observed significant changes to actuarial career development and advancement opportunities. But, those changes aren’t occurring in equal measures across the arc of the actuarial career. Our focus is on the impact felt by experienced reinsurance actuaries.

Description: In this interview, Caroline Grégoire, formerly from Hannover Re, and now international mentor, coach, trainer and speaker, shares her views on how mentoring can support you on your career path and how it also benefits the reinsurance industry as a whole.

Description: In this webcast, presenters will outline the key content in ERM ASOPs 46, 47 and 55 and explore the impact each ASOP has on practitioners working in these fields. We will also describe the revision work currently under way in the ERM Committee of the Actuarial Standards Board.

Description: Chairperson's Corner from the March 2004 issue of Reinsurance News.

Description: This session will provide an overview qualitative and quantitative assessment of climate risks of insurance companies

Description: This article reports on the latest annual survey about the relationship between reinsurers and their cedant clients. Some improvement was seen in 2011 from both actuaries and underwriters.

Description: Reunite with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, IFRS 17, product strategy, cross-border communication and discussion, and more. Advance your career through learning and networking opportunities, and share your experiences in the finance and insurance industries, as well as other fields related to actuarial science.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Discover the rapidly developing health and wellness industry during the Use of Health and Wellness Data in L&H Risk Assessment webcast. Our discussion includes the maximization of data usage through several different means, including current risk selection, creation of a dynamic ongoing assessment offering or substitution of traditional underwriting information to shorten the underwriting process. Come explore these different approaches as they affect the health and wellness industry. We will express the importance of a constantly changing data usage environment in order to better prepare insurers to maximize their data and drive health and wellness forward.